Aquestive Therapeutics AQST 深 沪
已收盘 08-14 16:00:00 美东时间
4.25
0.000
0.00%
华盛通- 最 高4.28
- 今 开4.20
- 成交量 435.01万股
- 最 低 4.015
- 昨 收 4.25
- 总市值 5.33亿
- 52周最高 7.55
- 市盈率 静 --
- 换手率 3.47%
- 52周最低 2.93
- 委 比 -21.16%
- 总股本 1.25亿
- 历史最高 20.696
- 量 比 0.76
- 振 幅 6.24%
- 历史最低 0.618
- 每 手 1
- 风险率 1.04%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aquestive Therapeutics Affirms FY2026 Sales Guidance of $46.000M-$50.000M vs $50.584M Est
Aquestive Therapeutics (NASDAQ:AQST) affirms FY2026 sales outlook from $46.000 million-$50.000 million to $46.000 million-$50.000 million vs $50.584 million estimate.
08-12 04:01
Aquestive Therapeutics shares are trading higher after the company announced results from its human factors validation study and pharmacokinetic study for Anaphylm sublingual film
Aquestive Therapeutics shares are trading higher after the company announced results from its human factors validation study and pharmacokinetic study for Anaphylm sublingual film
08-10 21:21
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film
Aquestive Therapeutics announced positive results from human factors and pharmacokinetic studies for Anaphylm™, supporting its planned NDA resubmission in Q3 2026. Key improvements include a revised packaging design reducing pouch-opening time from 17 seconds to 3 seconds, and updated instructions reducing incorrect film placement by over 80%. Pharmacokinetic results showed comparable efficacy between self-administration and clinician-administrat...
08-10 11:00
Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
Aquestive Therapeutics will report Q2 2026 results on August 11, 2026, and host an investor conference call on August 12 at 8:00 a.m. ET. Registration is required for participation. A live webcast and replay will be available on the company’s website. Aquestive, a pharmaceutical company specializing in innovative drug delivery technologies, is advancing products like Anaphylm™ and AQST-108 for various therapeutic indications.
07-29 11:00
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
Aquestive Therapeutics, Inc. announced that its management team will participate in the Leerink Partners Therapeutics Forum on July 14, 2026, to discuss key themes in immunology, inflammation, and metabolism, and host investor meetings. The company, a leader in oral film medications, develops innovative therapies like Anaphylm™ for severe allergic reactions and AQST-108 for dermatological conditions, using proprietary technologies such as PharmFi...
07-07 11:00
Aquestive Therapeutics Charts Cautious, Liquid Path Forward
Aquestive Therapeutics, Inc. (($AQST)) has held its Q1 earnings call. Read on f...
05-20 14:56
Aquestive Therapeutics Signals Momentum In Earnings Call
Aquestive Therapeutics, Inc. (($AQST)) has held its Q1 earnings call. Read on f...
05-15 08:26
Aquestive Therapeutics Q1 2026 Earnings Call: Complete Transcript
Aquestive Therapeutics (NASDAQ:AQST) held its first-quarter earnings conference...
05-14 21:09
Aquestive Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.
Aquestive Therapeutics shares are trading higher after the company reported bet...
05-14 04:40
Aquestive Therapeutics Affirms FY2026 Sales Guidance of $46.000M-$50.000M vs $48.072M Est
Aquestive Therapeutics (NASDAQ:AQST) affirms FY2026 sales outlook from $46.000 million-$50.000 million to $46.000 million-$50.000 million vs $48.072 million estimate.
05-14 04:02
